000269680 001__ 269680
000269680 005__ 20240808164539.0
000269680 0247_ $$2doi$$a10.1002/alz.13779
000269680 0247_ $$2pmid$$apmid:38506627
000269680 0247_ $$2pmc$$apmc:PMC11095427
000269680 0247_ $$2ISSN$$a1552-5260
000269680 0247_ $$2ISSN$$a1552-5279
000269680 0247_ $$2altmetric$$aaltmetric:161140070
000269680 037__ $$aDZNE-2024-00594
000269680 041__ $$aEnglish
000269680 082__ $$a610
000269680 1001_ $$00000-0003-4929-4137$$aLarsen, Frode Kibsgaard$$b0
000269680 245__ $$aAge of Alzheimer's disease diagnosis in people with Down syndrome and associated factors: Results from the Horizon 21 European Down syndrome consortium.
000269680 260__ $$aHoboken, NJ$$bWiley$$c2024
000269680 3367_ $$2DRIVER$$aarticle
000269680 3367_ $$2DataCite$$aOutput Types/Journal article
000269680 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1716453644_3153
000269680 3367_ $$2BibTeX$$aARTICLE
000269680 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000269680 3367_ $$00$$2EndNote$$aJournal Article
000269680 520__ $$aPeople with Down syndrome (DS) have high risk of developing Alzheimer's disease (AD). This study examined mean ages of AD diagnosis and associations with co-occurring conditions among adults with DS from five European countries.Data from 1335 people with DS from the Horizon 21 European DS Consortium were used for the analysis.Mean ages of AD diagnosis ranged between 51.4 (SD 7.0) years (United Kingdom) and 55.6 (SD 6.8) years (France). Sleep-related and mental health problems were associated with earlier age of AD diagnosis. The higher number of co-occurring conditions the more likely the person with DS is diagnosed with AD at an earlier age.Mean age of AD diagnosis in DS was relatively consistent across countries. However, co-occurring conditions varied and impacted on age of diagnosis, suggesting that improvements can be made in diagnosing and managing these conditions to delay onset of AD in DS.Mean age of AD diagnosis was relatively consistent between countries Sleep problems and mental health problems were associated with earlier age of AD diagnosis APOE ε4 carriers were diagnosed with AD at an earlier age compared to non-carriers Number of co-occurring conditions was associated with earlier age of AD diagnosis No differences between level of intellectual disability and mean age of AD diagnosis.
000269680 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000269680 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000269680 650_2 $$2MeSH$$aHumans
000269680 650_2 $$2MeSH$$aDown Syndrome: epidemiology
000269680 650_2 $$2MeSH$$aDown Syndrome: diagnosis
000269680 650_2 $$2MeSH$$aDown Syndrome: complications
000269680 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000269680 650_2 $$2MeSH$$aAlzheimer Disease: epidemiology
000269680 650_2 $$2MeSH$$aMale
000269680 650_2 $$2MeSH$$aFemale
000269680 650_2 $$2MeSH$$aMiddle Aged
000269680 650_2 $$2MeSH$$aEurope: epidemiology
000269680 650_2 $$2MeSH$$aAdult
000269680 650_2 $$2MeSH$$aUnited Kingdom: epidemiology
000269680 650_2 $$2MeSH$$aSleep Wake Disorders: epidemiology
000269680 650_2 $$2MeSH$$aSleep Wake Disorders: diagnosis
000269680 650_2 $$2MeSH$$aAge Factors
000269680 650_2 $$2MeSH$$aAge of Onset
000269680 650_2 $$2MeSH$$aFrance: epidemiology
000269680 650_2 $$2MeSH$$aAged
000269680 650_2 $$2MeSH$$aComorbidity
000269680 650_2 $$2MeSH$$aApolipoprotein E4: genetics
000269680 650_7 $$2Other$$aco‐occurring conditions
000269680 650_7 $$2Other$$aAlzheimer's disease
000269680 650_7 $$2Other$$aDown syndrome
000269680 650_7 $$2Other$$aage of diagnosis
000269680 650_7 $$2Other$$aco‐occurring conditions
000269680 7001_ $$00000-0001-6596-2145$$aBaksh, R Asaad$$b1
000269680 7001_ $$aMcGlinchey, Eimear$$b2
000269680 7001_ $$aLangballe, Ellen Melbye$$b3
000269680 7001_ $$aBenejam, Bessy$$b4
000269680 7001_ $$aBeresford-Webb, Jessica$$b5
000269680 7001_ $$aMcCarron, Mary$$b6
000269680 7001_ $$aCoppus, Antonia$$b7
000269680 7001_ $$aFalquero, Segolene$$b8
000269680 7001_ $$aFortea, Juan$$b9
000269680 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b10$$udzne
000269680 7001_ $$aLoosli, Sandra V$$b11
000269680 7001_ $$aMark, Ruth$$b12
000269680 7001_ $$aRebillat, Anne-Sophie$$b13
000269680 7001_ $$aZaman, Shahid$$b14
000269680 7001_ $$aStrydom, Andre$$b15
000269680 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.13779$$gVol. 20, no. 5, p. 3270 - 3280$$n5$$p3270 - 3280$$tAlzheimer's and dementia$$v20$$x1552-5260$$y2024
000269680 8564_ $$uhttps://pub.dzne.de/record/269680/files/DZNE-2024-00594%20SUP.pdf
000269680 8564_ $$uhttps://pub.dzne.de/record/269680/files/DZNE-2024-00594.pdf$$yOpenAccess
000269680 8564_ $$uhttps://pub.dzne.de/record/269680/files/DZNE-2024-00594%20SUP.pdf?subformat=pdfa$$xpdfa
000269680 8564_ $$uhttps://pub.dzne.de/record/269680/files/DZNE-2024-00594.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000269680 909CO $$ooai:pub.dzne.de:269680$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000269680 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000269680 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000269680 9141_ $$y2024
000269680 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000269680 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000269680 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000269680 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000269680 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-25$$wger
000269680 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000269680 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000269680 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000269680 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000269680 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000269680 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000269680 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000269680 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x0
000269680 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000269680 980__ $$ajournal
000269680 980__ $$aVDB
000269680 980__ $$aUNRESTRICTED
000269680 980__ $$aI:(DE-2719)1111016
000269680 980__ $$aI:(DE-2719)1111015
000269680 9801_ $$aFullTexts